CytRx to Present at the 19th Annual BIO CEO & Investor Conference

LOS ANGELES, Feb. 6, 2017 /PRNewswire/ — CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice President of Business Development and Investor Relations, will present a corporate update at the 19th Annual BIO CEO & Investor Conference on Monday, February 13th at 4:00 p.m. Eastern Time at the Waldorf Astoria Hotel in New York City.

Based on positive, statistically significant results from CytRx’s pivotal Phase 3 trial evaluating aldoxorubicin compared to investigator’s choice in patients with previously treated relapsed or refractory sarcomas, CytRx is scheduled to meet with the FDA this quarter to discuss the regulatory path for a New Drug Application (NDA).

A live and archived webcast of the presentation will be available at http://www.veracast.com/webcasts/bio/ceoinvestor2017/42130220022.cfm.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin, its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx is also expanding its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx’s expertise in albumin biology and linker technology for the development of a new class of anti-cancer therapies.

About the BIO CEO & Investor Conference

Now in its 19th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. The conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks relating to the outcome, timing and results of CytRx’s clinical testing of aldoxorubicin and preclinical testing of its LADR™ linker technology platform, the outcome, timing or results of CytRx’s clinical testing of aldoxorubicin, the risk that any future pre-clinical or human testing of compounds based on the LADR™ technology platform might not show efficacy or reduced side effects of those compounds, risks related to CytRx’s ability to manufacture its drug candidates in a timely fashion, cost-effectively or in commercial quantities in compliance with stringent regulatory requirements, risks related to CytRx’s need for additional capital or strategic partnerships to fund its ongoing working capital needs and development efforts, including the Phase 2 and Phase 3 clinical development of aldoxorubicin for SCLC and STS, respectively, and the preclinical and clinical development of compounds based on the LADR™ technology platform, risks related to lawsuits that have been brought against the Company and its officers and/or directors for alleged violations of the securities laws, and the risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx’s most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact: CytRx Corporation David J. Haen Vice President, Business Development and Investor Relations (310) 826-5648, ext 304 dhaen@cytrx.com

Investor Relations Contact: Argot Partners Michelle Carroll (212) 600-1902 michelle@argotpartners.com

SOURCE CytRx Corporation

CytRx to Present at the 19th Annual BIO CEO & Investor Conference

LOS ANGELES, Feb. 6, 2017 /PRNewswire/ — CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice President of Business Development and Investor Relations, will present a corporate update at the 19th Annual BIO CEO & Investor Conference on Monday, February 13th at 4:00 p.m. Eastern Time at the Waldorf Astoria Hotel in New York City.

Based on positive, statistically significant results from CytRx’s pivotal Phase 3 trial evaluating aldoxorubicin compared to investigator’s choice in patients with previously treated relapsed or refractory sarcomas, CytRx is scheduled to meet with the FDA this quarter to discuss the regulatory path for a New Drug Application (NDA).

A live and archived webcast of the presentation will be available at http://www.veracast.com/webcasts/bio/ceoinvestor2017/42130220022.cfm.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin, its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx is also expanding its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx’s expertise in albumin biology and linker technology for the development of a new class of anti-cancer therapies.

About the BIO CEO & Investor Conference

Now in its 19th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. The conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks relating to the outcome, timing and results of CytRx’s clinical testing of aldoxorubicin and preclinical testing of its LADR™ linker technology platform, the outcome, timing or results of CytRx’s clinical testing of aldoxorubicin, the risk that any future pre-clinical or human testing of compounds based on the LADR™ technology platform might not show efficacy or reduced side effects of those compounds, risks related to CytRx’s ability to manufacture its drug candidates in a timely fashion, cost-effectively or in commercial quantities in compliance with stringent regulatory requirements, risks related to CytRx’s need for additional capital or strategic partnerships to fund its ongoing working capital needs and development efforts, including the Phase 2 and Phase 3 clinical development of aldoxorubicin for SCLC and STS, respectively, and the preclinical and clinical development of compounds based on the LADR™ technology platform, risks related to lawsuits that have been brought against the Company and its officers and/or directors for alleged violations of the securities laws, and the risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx’s most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact: CytRx Corporation David J. Haen Vice President, Business Development and Investor Relations (310) 826-5648, ext 304 dhaen@cytrx.com

Investor Relations Contact: Argot Partners Michelle Carroll (212) 600-1902 michelle@argotpartners.com

SOURCE CytRx Corporation

CytRx to Present at the 19th Annual BIO CEO & Investor Conference

LOS ANGELES, Feb. 6, 2017 /PRNewswire/ — CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice President of Business Development and Investor Relations, will present a corporate update at the 19th Annual BIO CEO & Investor Conference on Monday, February 13th at 4:00 p.m. Eastern Time at the Waldorf Astoria Hotel in New York City.

Based on positive, statistically significant results from CytRx’s pivotal Phase 3 trial evaluating aldoxorubicin compared to investigator’s choice in patients with previously treated relapsed or refractory sarcomas, CytRx is scheduled to meet with the FDA this quarter to discuss the regulatory path for a New Drug Application (NDA).

A live and archived webcast of the presentation will be available at http://www.veracast.com/webcasts/bio/ceoinvestor2017/42130220022.cfm.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin, its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx is also expanding its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx’s expertise in albumin biology and linker technology for the development of a new class of anti-cancer therapies.

About the BIO CEO & Investor Conference

Now in its 19th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. The conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks relating to the outcome, timing and results of CytRx’s clinical testing of aldoxorubicin and preclinical testing of its LADR™ linker technology platform, the outcome, timing or results of CytRx’s clinical testing of aldoxorubicin, the risk that any future pre-clinical or human testing of compounds based on the LADR™ technology platform might not show efficacy or reduced side effects of those compounds, risks related to CytRx’s ability to manufacture its drug candidates in a timely fashion, cost-effectively or in commercial quantities in compliance with stringent regulatory requirements, risks related to CytRx’s need for additional capital or strategic partnerships to fund its ongoing working capital needs and development efforts, including the Phase 2 and Phase 3 clinical development of aldoxorubicin for SCLC and STS, respectively, and the preclinical and clinical development of compounds based on the LADR™ technology platform, risks related to lawsuits that have been brought against the Company and its officers and/or directors for alleged violations of the securities laws, and the risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx’s most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact: CytRx Corporation David J. Haen Vice President, Business Development and Investor Relations (310) 826-5648, ext 304 dhaen@cytrx.com

Investor Relations Contact: Argot Partners Michelle Carroll (212) 600-1902 michelle@argotpartners.com

SOURCE CytRx Corporation

CytRx to Present at the 19th Annual BIO CEO & Investor Conference

LOS ANGELES, Feb. 6, 2017 /PRNewswire/ — CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice President of Business Development and Investor Relations, will present a corporate update at the 19th Annual BIO CEO & Investor Conference on Monday, February 13th at 4:00 p.m. Eastern Time at the Waldorf Astoria Hotel in New York City.

Based on positive, statistically significant results from CytRx’s pivotal Phase 3 trial evaluating aldoxorubicin compared to investigator’s choice in patients with previously treated relapsed or refractory sarcomas, CytRx is scheduled to meet with the FDA this quarter to discuss the regulatory path for a New Drug Application (NDA).

A live and archived webcast of the presentation will be available at http://www.veracast.com/webcasts/bio/ceoinvestor2017/42130220022.cfm.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin, its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx is also expanding its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx’s expertise in albumin biology and linker technology for the development of a new class of anti-cancer therapies.

About the BIO CEO & Investor Conference

Now in its 19th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. The conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks relating to the outcome, timing and results of CytRx’s clinical testing of aldoxorubicin and preclinical testing of its LADR™ linker technology platform, the outcome, timing or results of CytRx’s clinical testing of aldoxorubicin, the risk that any future pre-clinical or human testing of compounds based on the LADR™ technology platform might not show efficacy or reduced side effects of those compounds, risks related to CytRx’s ability to manufacture its drug candidates in a timely fashion, cost-effectively or in commercial quantities in compliance with stringent regulatory requirements, risks related to CytRx’s need for additional capital or strategic partnerships to fund its ongoing working capital needs and development efforts, including the Phase 2 and Phase 3 clinical development of aldoxorubicin for SCLC and STS, respectively, and the preclinical and clinical development of compounds based on the LADR™ technology platform, risks related to lawsuits that have been brought against the Company and its officers and/or directors for alleged violations of the securities laws, and the risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx’s most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact: CytRx Corporation David J. Haen Vice President, Business Development and Investor Relations (310) 826-5648, ext 304 dhaen@cytrx.com

Investor Relations Contact: Argot Partners Michelle Carroll (212) 600-1902 michelle@argotpartners.com

SOURCE CytRx Corporation

RentRange Becomes Data Provider for Cozy

Property management platform’s 100,000+ landlords will have access to data for more than 10 million individual investment properties across the U.S.

LUXEMBOURG–(Marketwired – February 06, 2017) – RentRange, one of the premier providers of market data and analytics for the housing industry, announced that they have begun providing data to Cozy, a leading provider of property management software. Through the agreement, more than 100,000 landlords using Cozy’s software to manage rentals will have access to detailed property reports — including rent estimates, rent benchmarks, estimated property vacancy rate, rental saturation and other helpful information for maximizing return on investment properties — based on the RentRange® data.

“Real estate investing is becoming increasingly data-driven, making it easier than ever for property owners and landlords to pinpoint the optimal rental rate for an individual property,” said Wally Charnoff, chief executive officer, RentRange Data Services. “Cozy has built an incredible user base by making property management more efficient for landlords and their renters. By working together to make RentRange data readily accessible to these users, we will expand the role that technology plays by helping landlords become better informed about local market conditions using detailed rental data.”

RentRange provides data to landlords and real estate investors that may be used to make data-informed decisions about the single-family residential market. The suite of data solutions includes RentRange’s Property Reports and Market Metric Reports. The Property Reports rely on RentRange’s proprietary algorithm to calculate rent estimates based on a variety of market- and property-level analytics, which can assist landlords in determining property values and setting monthly rents. The Market Metric Reports detail geography-based historical and current market-level trends that may be used to inform landlords of future investment strategies.

“We are constantly improving the rental management experience, and adding data intelligence to better equip landlords’ decision-making is the next step in helping our customers work more efficiently,” said Gino Zahnd, CEO of Cozy. “RentRange has established itself as the go-to source for address- and market-level data, and we are excited to be able to make their comprehensive and up-to-date information available to our landlord customer base.”

About Cozy

Cozy (www.cozy.co) makes renting easy for landlords, property managers, and tenants. Simple rent payments, online rental applications, and secure tenant screening make Cozy the best way for managers and renters to interact through the entire rental lifecycle.

About RentRange Data Services

RentRange Data Services is an innovative marketing services company specializing in U.S. real estate. The company provides marketing services to Investability Real Estate, Inc., Investability and RentRange.

About RentRange®

RentRange is one of the nation’s premier providers of information for the singlefamily residential sector, delivering address- and market-level rental data, analytics and rent-based valuation solutions for a diverse customer base. The RentRange® reports help customers make datainformed decisions about the singlefamily residential market. The RentRange suite of data solutions includes individual property reports, market metric reports, customized data and analytics and singlefamily residential investor lists. RentRange is part of the Altisource Portfolio Solutions S.A. (NASDAQ: ASPS) family of businesses.

About Altisource®

Altisource Portfolio Solutions S.A. (NASDAQ: ASPS) is a premier marketplace and transaction solutions provider for the real estate, mortgage and consumer debt industries. Altisource’s proprietary business processes, vendor and electronic payment management software and behavioral science-based analytics improve outcomes for marketplace participants. Additional information is available at altisource.com.

White Mushroom Market Research Key Players, Industry Overview, Supply Chain and Analysis to 2021

The White Mushroom Market research report is a professional and in-depth study on the current state of the White Mushroom Industry.

The Report provides a basic overview of the White Mushroom Market including definitions, classifications, applications and chain structure. The White Mushroom Industry analysis is provided for the international market including development history, competitive landscape analysis, and major regions development status.

To begin with, the report elaborates the White Mushroom Market overview. Various definitions and classification of the industry, applications of the industry and chain structure are given. Present day status of the White Mushroom Market in key regions is stated and industry policies and news are analysed.

Browse Detailed TOC, Tables, Figures, Charts and Companies Mentioned in White Mushroom Market @ http://www.360marketupdates.com/10411236

Next part of the White Mushroom Market analysis report speaks about the manufacturing process. The process is analysed thoroughly with respect three points, viz. raw material and equipment suppliers, various manufacturing associated costs (material cost, labour cost, etc.) and the actual process.

Major Manufacturers analysed in White Mushroom Market are:

  • Banken Champignons
  • Agro Dutch
  • Bonduelle
  • Hkoto
  • Hughes
  • Scelta Mushrooms
  • Monaghan
  • C4C Holding
  • China Greenfresh
  • yukiguni Maitake
  • Costa Group

Get Sample PDF of report at @ http://www.360marketupdates.com/enquiry/request-sample/10411236

After the basic information, the report sheds light on the production. Production plants, their capacities, global production and revenue are studied. Also, the White Mushroom Market growth in various regions and R&D status are also covered.

Further in the report, the White Mushroom Market is examined for price, cost and gross. These three points are analysed for types, companies and regions. In continuation with this data sale price is for various types, applications and region is also included. The White Mushroom Industry consumption for major regions is given. Additionally, type wise and application wise consumption figures are also given.

Analysis also include consumption. Import and export data for Regions North America, Europe, China, Japan, Southeast Asia, India.

Ask for Discount @ http://www.360marketupdates.com/enquiry/request-discount/10411236

With the help of supply and consumption data, gap between these two is also explained.
To provide information on competitive landscape, this report includes detailed profiles of White Mushroom Market key players. For each player, product details, capacity, price, cost, gross and revenue numbers are given. Their contact information is provided for better understanding.

Other Major Topics Covered in White Mushroom market research report are as follows:

  • Marketing Strategy Analysis, Distributors/Traders
  • Marketing Channel
  • Direct Marketing
  • Indirect Marketing
  • Marketing Channel Development Trend
  • Market Positioning
  • Pricing Strategy
  • Brand Strategy
  • Target Client
  • Distributors/Traders List

Market Effect Factors Analysis

  • Technology Progress/Risk
  • Substitutes Threat
  • Technology Progress in Related Industry
  • Consumer Needs/Customer Preference Change
  • Economic/Political Environmental Change

Global White Mushroom Market Forecast 2016-2016

  • Global White Mushroom Capacity, Production, Revenue Forecast 2016-2016
  • Global White Mushroom Production, Consumption Forecast by Regions 2016-2016
  • Global White Mushroom Production Forecast by Type 2016-2016
  • Global White Mushroom Consumption Forecast by Application 2016-2016
  • White Mushroom Price Forecast 2016-2016

Purchase this report @ http://www.360marketupdates.com/purchase/10411236    

In this White Mushroom Market analysis, traders and distributors analysis is given along with contact details. For material and equipment suppliers also, contact details are given. New investment feasibility analysis is included in the report.

No. of Pages: 114

Price of Report: $2900 (Single User Licence)

Speak to Expert @ http://www.360marketupdates.com/enquiry/pre-order-enquiry/10411236

About 360 Market Updates:
360 Market Updates is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments.
Contact–
Mr. Ameya Pingaley
360 Market Updates
+1 408 520 9750
Email – sales@360marketupdates.com

White Mushroom Market Research Key Players, Industry Overview, Supply Chain and Analysis to 2021

The White Mushroom Market research report is a professional and in-depth study on the current state of the White Mushroom Industry.

The Report provides a basic overview of the White Mushroom Market including definitions, classifications, applications and chain structure. The White Mushroom Industry analysis is provided for the international market including development history, competitive landscape analysis, and major regions development status.

To begin with, the report elaborates the White Mushroom Market overview. Various definitions and classification of the industry, applications of the industry and chain structure are given. Present day status of the White Mushroom Market in key regions is stated and industry policies and news are analysed.

Browse Detailed TOC, Tables, Figures, Charts and Companies Mentioned in White Mushroom Market @ http://www.360marketupdates.com/10411236

Next part of the White Mushroom Market analysis report speaks about the manufacturing process. The process is analysed thoroughly with respect three points, viz. raw material and equipment suppliers, various manufacturing associated costs (material cost, labour cost, etc.) and the actual process.

Major Manufacturers analysed in White Mushroom Market are:

  • Banken Champignons
  • Agro Dutch
  • Bonduelle
  • Hkoto
  • Hughes
  • Scelta Mushrooms
  • Monaghan
  • C4C Holding
  • China Greenfresh
  • yukiguni Maitake
  • Costa Group

Get Sample PDF of report at @ http://www.360marketupdates.com/enquiry/request-sample/10411236

After the basic information, the report sheds light on the production. Production plants, their capacities, global production and revenue are studied. Also, the White Mushroom Market growth in various regions and R&D status are also covered.

Further in the report, the White Mushroom Market is examined for price, cost and gross. These three points are analysed for types, companies and regions. In continuation with this data sale price is for various types, applications and region is also included. The White Mushroom Industry consumption for major regions is given. Additionally, type wise and application wise consumption figures are also given.

Analysis also include consumption. Import and export data for Regions North America, Europe, China, Japan, Southeast Asia, India.

Ask for Discount @ http://www.360marketupdates.com/enquiry/request-discount/10411236

With the help of supply and consumption data, gap between these two is also explained.
To provide information on competitive landscape, this report includes detailed profiles of White Mushroom Market key players. For each player, product details, capacity, price, cost, gross and revenue numbers are given. Their contact information is provided for better understanding.

Other Major Topics Covered in White Mushroom market research report are as follows:

  • Marketing Strategy Analysis, Distributors/Traders
  • Marketing Channel
  • Direct Marketing
  • Indirect Marketing
  • Marketing Channel Development Trend
  • Market Positioning
  • Pricing Strategy
  • Brand Strategy
  • Target Client
  • Distributors/Traders List

Market Effect Factors Analysis

  • Technology Progress/Risk
  • Substitutes Threat
  • Technology Progress in Related Industry
  • Consumer Needs/Customer Preference Change
  • Economic/Political Environmental Change

Global White Mushroom Market Forecast 2016-2016

  • Global White Mushroom Capacity, Production, Revenue Forecast 2016-2016
  • Global White Mushroom Production, Consumption Forecast by Regions 2016-2016
  • Global White Mushroom Production Forecast by Type 2016-2016
  • Global White Mushroom Consumption Forecast by Application 2016-2016
  • White Mushroom Price Forecast 2016-2016

Purchase this report @ http://www.360marketupdates.com/purchase/10411236    

In this White Mushroom Market analysis, traders and distributors analysis is given along with contact details. For material and equipment suppliers also, contact details are given. New investment feasibility analysis is included in the report.

No. of Pages: 114

Price of Report: $2900 (Single User Licence)

Speak to Expert @ http://www.360marketupdates.com/enquiry/pre-order-enquiry/10411236

About 360 Market Updates:
360 Market Updates is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments.
Contact–
Mr. Ameya Pingaley
360 Market Updates
+1 408 520 9750
Email – sales@360marketupdates.com

White Mushroom Market Research Key Players, Industry Overview, Supply Chain and Analysis to 2021

The White Mushroom Market research report is a professional and in-depth study on the current state of the White Mushroom Industry.

The Report provides a basic overview of the White Mushroom Market including definitions, classifications, applications and chain structure. The White Mushroom Industry analysis is provided for the international market including development history, competitive landscape analysis, and major regions development status.

To begin with, the report elaborates the White Mushroom Market overview. Various definitions and classification of the industry, applications of the industry and chain structure are given. Present day status of the White Mushroom Market in key regions is stated and industry policies and news are analysed.

Browse Detailed TOC, Tables, Figures, Charts and Companies Mentioned in White Mushroom Market @ http://www.360marketupdates.com/10411236

Next part of the White Mushroom Market analysis report speaks about the manufacturing process. The process is analysed thoroughly with respect three points, viz. raw material and equipment suppliers, various manufacturing associated costs (material cost, labour cost, etc.) and the actual process.

Major Manufacturers analysed in White Mushroom Market are:

  • Banken Champignons
  • Agro Dutch
  • Bonduelle
  • Hkoto
  • Hughes
  • Scelta Mushrooms
  • Monaghan
  • C4C Holding
  • China Greenfresh
  • yukiguni Maitake
  • Costa Group

Get Sample PDF of report at @ http://www.360marketupdates.com/enquiry/request-sample/10411236

After the basic information, the report sheds light on the production. Production plants, their capacities, global production and revenue are studied. Also, the White Mushroom Market growth in various regions and R&D status are also covered.

Further in the report, the White Mushroom Market is examined for price, cost and gross. These three points are analysed for types, companies and regions. In continuation with this data sale price is for various types, applications and region is also included. The White Mushroom Industry consumption for major regions is given. Additionally, type wise and application wise consumption figures are also given.

Analysis also include consumption. Import and export data for Regions North America, Europe, China, Japan, Southeast Asia, India.

Ask for Discount @ http://www.360marketupdates.com/enquiry/request-discount/10411236

With the help of supply and consumption data, gap between these two is also explained.
To provide information on competitive landscape, this report includes detailed profiles of White Mushroom Market key players. For each player, product details, capacity, price, cost, gross and revenue numbers are given. Their contact information is provided for better understanding.

Other Major Topics Covered in White Mushroom market research report are as follows:

  • Marketing Strategy Analysis, Distributors/Traders
  • Marketing Channel
  • Direct Marketing
  • Indirect Marketing
  • Marketing Channel Development Trend
  • Market Positioning
  • Pricing Strategy
  • Brand Strategy
  • Target Client
  • Distributors/Traders List

Market Effect Factors Analysis

  • Technology Progress/Risk
  • Substitutes Threat
  • Technology Progress in Related Industry
  • Consumer Needs/Customer Preference Change
  • Economic/Political Environmental Change

Global White Mushroom Market Forecast 2016-2016

  • Global White Mushroom Capacity, Production, Revenue Forecast 2016-2016
  • Global White Mushroom Production, Consumption Forecast by Regions 2016-2016
  • Global White Mushroom Production Forecast by Type 2016-2016
  • Global White Mushroom Consumption Forecast by Application 2016-2016
  • White Mushroom Price Forecast 2016-2016

Purchase this report @ http://www.360marketupdates.com/purchase/10411236    

In this White Mushroom Market analysis, traders and distributors analysis is given along with contact details. For material and equipment suppliers also, contact details are given. New investment feasibility analysis is included in the report.

No. of Pages: 114

Price of Report: $2900 (Single User Licence)

Speak to Expert @ http://www.360marketupdates.com/enquiry/pre-order-enquiry/10411236

About 360 Market Updates:
360 Market Updates is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments.
Contact–
Mr. Ameya Pingaley
360 Market Updates
+1 408 520 9750
Email – sales@360marketupdates.com

Jennifer Rhodes Joins Tagence as Executive Vice President

Tagence, Inc announces Jennifer M. Rhodes as the new Executive Vice President

FOR IMMEDIATE RELEASE

Tagence, Inc., an information management technology consulting company, today announced that Jennifer M. Rhodes has joined the company as Executive Vice President.

Ms. Rhodes is a transformational business leader with experience across multiple industries including healthcare, business consulting, the nonprofit sector and federal contracting. Most recently, she developed a Strategic Communication practice group as a Principal of Knowesis, Inc. At Tagence she will lead strategic growth initiatives and build on our existing culture of responsive service and excellent delivery.

“Jennifer makes a positive impact wherever she goes. She has a proven track record for growing businesses and developing top talent. We are excited to have her join our team,” said Anna Jullien, President of Tagence. “Additionally, every information management project is also a change management project and Jennifer’s expertise in that area will be a real benefit to our clients, especially in the planning stages.”

“It is an honor to join the team here at Tagence. This company has an impressive history and a distinctive culture of excellence. It is thrilling to be a part of a company that is focused on making an immediate and lasting impact on business productivity and compliance for its clients. I look forward to the great things Tagence will do in the months and years ahead,” said Ms. Rhodes.

About Tagence
Tagence, Inc. is a Service-Disabled Veteran-Owned Small Business (SDVOSB) located in Leesburg, Virginia, providing information management services to government and commercial clients. With specialized expertise in information governance and 5015.2-compliant records management, Tagence enables organizations to find, control, understand and use all of their data in support of their agencies’ core missions. Clients include Department of Defense, Federal Aviation Administration, Securities and Exchange Commission, Yum!, Tyson Foods, and others.

Jennifer Rhodes Joins Tagence as Executive Vice President

Tagence, Inc announces Jennifer M. Rhodes as the new Executive Vice President

FOR IMMEDIATE RELEASE

Tagence, Inc., an information management technology consulting company, today announced that Jennifer M. Rhodes has joined the company as Executive Vice President.

Ms. Rhodes is a transformational business leader with experience across multiple industries including healthcare, business consulting, the nonprofit sector and federal contracting. Most recently, she developed a Strategic Communication practice group as a Principal of Knowesis, Inc. At Tagence she will lead strategic growth initiatives and build on our existing culture of responsive service and excellent delivery.

“Jennifer makes a positive impact wherever she goes. She has a proven track record for growing businesses and developing top talent. We are excited to have her join our team,” said Anna Jullien, President of Tagence. “Additionally, every information management project is also a change management project and Jennifer’s expertise in that area will be a real benefit to our clients, especially in the planning stages.”

“It is an honor to join the team here at Tagence. This company has an impressive history and a distinctive culture of excellence. It is thrilling to be a part of a company that is focused on making an immediate and lasting impact on business productivity and compliance for its clients. I look forward to the great things Tagence will do in the months and years ahead,” said Ms. Rhodes.

About Tagence
Tagence, Inc. is a Service-Disabled Veteran-Owned Small Business (SDVOSB) located in Leesburg, Virginia, providing information management services to government and commercial clients. With specialized expertise in information governance and 5015.2-compliant records management, Tagence enables organizations to find, control, understand and use all of their data in support of their agencies’ core missions. Clients include Department of Defense, Federal Aviation Administration, Securities and Exchange Commission, Yum!, Tyson Foods, and others.